Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 3/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | RORC | P51449 | 5/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6694605 | 1.00 | PDE4B (0.51) | PDE4BMEN1KMT2ATACR1SCN9A | |
| SCHEMBL12602246 | 1.00 | PDE4B (0.51) | PDE4BMEN1KMT2ATACR1SCN9A | |
| SCHEMBL5451966 | 1.00 | PDE4B (0.51) | PDE4BMEN1KMT2ATACR1SCN9A | |
| SCHEMBL15144418 | 1.00 | PDE4B (0.51) | PDE4BMEN1KMT2ATACR1SCN9A | |
| SCHEMBL6694614 | 1.00 | PDE4B (0.51) | PDE4BMEN1KMT2ATACR1SCN9A | |
| SCHEMBL3065548 | 1.00 | PDE4B (0.51) | PDE4BMEN1KMT2ATACR1SCN9A | |
| SCHEMBL3054630 | 0.91 | MEN1 (0.44) | PDE4BMEN1KMT2ATACR1SCN9A | |
| SCHEMBL14934670 | 0.91 | PDE4B (0.51) | PDE4BMEN1KMT2ATACR1HDAC1 | |
| SCHEMBL3008782 | 0.91 | PDE4B (0.51) | PDE4BMEN1KMT2ATACR1HDAC1 | |
| SCHEMBL18780248 | 0.91 | PDE4B (0.51) | PDE4BMEN1KMT2ATACR1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0812827-A1 | Piperidine derivative as intermediates for the preparation of paroxetine and process for their preparation | SUMIKA FINE CHEMICALS Co., Ltd. (JP) | 1997-12-17 | — | — | EP | claimed |
| US-12054484-B2 | Substituted tetrahydropyrans as CCR2 modulators | CHEMOCENTRYX, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| WO-2023102477-A1 | PERIPHERALLY AND LUMINALLY-RESTRICTED INHIBITORS OF THE SEROTONIN TRANSPORTER AS TREATMENTS FOR DISORDERS OF GASTROINTESTINAL MOTILITY | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-06-08 | — | — | WO | disclosed |
| US-20220153733-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2022-05-19 | — | — | US | disclosed |
| US-20220153733-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2022-05-19 | — | — | US | disclosed |
| EP-3313396-B1 | G PROTEIN-COUPLED RECEPTOR KINASE INHIBITORS AND METHODS FOR USE OF THE SAME | UNIV MICHIGAN REGENTS (US) | 2021-12-15 | — | — | EP | disclosed |
| EP-3297438-B1 | CCR2 MODULATORS | CHEMOCENTRYX INC (US) | 2021-10-20 | — | — | EP | disclosed |
| US-20200121688-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2020-04-23 | — | — | US | disclosed |
| US-20200121688-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2020-04-23 | — | — | US | disclosed |
| US-10464934-B2 | Substituted tetrahydropyrans as CCR2 modulators | CHEMOCENTRYX, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| WO-2007016431-A2 | NOVEL BENZO [D] [1,3]-DIOXOL DERIVATIVES | CONCERT PHARMACEUTICALS INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| US-6815548-B2 | MINTERMEDIATE FOR PHARMACEUTICALS SUCH AS PAROXETINE USEFUL AS ANTIDEPRESSANTS, REPRESENTED BY THE GENERAL FORMULA (I): | SUMIKA FINE CHEMICALS CO., LTD. (JP) | 2004-11-09 | — | — | US | disclosed |
| EP-1394160-A1 | Process for preparing crystalline paroxetin hydrochloride | SUMIKA FINE CHEMICALS Co., Ltd. (JP) | 2004-03-03 | — | — | EP | disclosed |
| EP-1384720-A1 | Process for drying paroxetine hydrochloride | SUMIKA FINE CHEMICALS Co., Ltd. (JP) | 2004-01-28 | — | — | EP | disclosed |
| EP-1384711-A1 | Optical resolution of a piperidine derivative | SUMIKA FINE CHEMICALS Co., Ltd. (JP) | 2004-01-28 | — | — | EP | disclosed |
| US-6610851-B1 | 1-tert-butoxycarbonyl-4-(4-fluorophenyl)-3-((3,4-methylene dioxyphenyl)oxymethyl)piperidine; reacting 4-(4-fluorophenyl)-3-hydroxymethylpiperidine with di-tert-butyl dicarbonate to form the carbamate; 3,4-methylenedioxyphenol | SUMIKA FINE CHEMICALS CO., LTD. (JP) | 2003-08-26 | — | — | US | disclosed |
| US-20030144519-A1 | Process for preparing a piperidine derivative | SUMIKA FINE CHEMICALS CO., LTD. | 2003-07-31 | — | — | US | disclosed |
| US-6476227-B1 | Piperidine derivative and process for preparing the same | SUMIKA FINE CHEMICALS CO., LTD. (JP) | 2002-11-05 | — | — | US | disclosed |
| US-5948914-A | PREPARING 4-(4-FLUOROPHENYL)-3-HYDROXYMETHYLPIPERIDINE BY OPTICALLY RESOLVING WITH O-CHLOROTARTRANILIC ACID; CHEMICAL INTERMEDIATE FOR DRUGS | SUMIKA FINE CHEMICALS CO., LTD. (JP) | 1999-09-07 | — | — | US | disclosed |
| EP-0812827-A1 | Piperidine derivative as intermediates for the preparation of paroxetine and process for their preparation | SUMIKA FINE CHEMICALS Co., Ltd. (JP) | 1997-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10464934-B2 | Substituted tetrahydropyrans as CCR2 modulators | CCR2, CCR1, CCR5 | PDE4B 2315/4885MEN1 4868/4885KMT2A 4009/4885 |
| US-12054484-B2 | Substituted tetrahydropyrans as CCR2 modulators | CCR2, CCR1, CCR5 | PDE4B 2716/4885MEN1 4860/4885KMT2A 4485/4885 |
| US-20030144519-A1 | Process for preparing a piperidine derivative | TPH1, TPH2, HTR7 | PDE4B 2857/4885MEN1 4248/4885KMT2A 442/4885 |
| US-20200121688-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CCR2, CCR1, CCR5 | PDE4B 2315/4885MEN1 4868/4885KMT2A 4009/4885 |
| US-20220153733-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CCR2, CCR1, CCR5 | PDE4B 2687/4885MEN1 4864/4885KMT2A 4477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.